The board of Parmax Pharma approved a preferential issue of shares and warrants at its meeting held on 29 August 2026. According to reports from Business Standard, the company has authorized the issuance of 31,37,586 equity shares of face value ₹10 each at an issue price of ₹36.50 per share, aggregating to ₹11.45 crore. Additionally, the board approved the issuance of 21,45,145 convertible warrants of face value ₹10 each at the same issue price of ₹36.50 per warrant.
The preferential issue comprises ₹11.45 crore in equity shares and ₹11.45 crore in convertible warrants, totaling ₹22.90 crore in aggregate value. As reported by Business Standard, both components are priced at ₹36.50 per share/warrant, maintaining uniform pricing across the equity and warrant components. The warrants are convertible instruments that provide the holder with the right to convert them into equity shares at a predetermined conversion ratio.
The preferential issue announcement was made on 29 August 2026 and represents a significant capital raising initiative by Parmax Pharma. According to Business Standard, the company has structured the issue to include both equity shares and convertible warrants, providing flexibility in capital utilization and potential future equity dilution management. The approval demonstrates the board's confidence in the company's growth prospects and funding requirements for business expansion.
